Pharmaceuticals & Biotech Norwegian Investing Ideas

NOK 32.5
33.2% undervalued intrinsic discount
Revenue
17.44% p.a.
Profit Margin
27.05%
Future PE
38.8x
Price in 2029
NOK 39.35
NOK 3.5
24.6% overvalued intrinsic discount
Profit Margin
15.44%
Future PE
54.41x
Price in 2029
NOK 4.24
NOK 82.5
14.7% undervalued intrinsic discount
Revenue
7.69% p.a.
Profit Margin
9.6%
Future PE
38.61x
Price in 2028
NOK 97.35